{"id":409061,"date":"2019-08-28T00:00:00","date_gmt":"2019-08-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0008-2019-biopharma-alopecia-niche-rare-disease-landscape-forecast-us-eu5-2019\/"},"modified":"2026-04-16T11:24:52","modified_gmt":"2026-04-16T11:24:52","slug":"nrlfim0008-2019-biopharma-alopecia-niche-rare-disease-landscape-forecast-us-eu5-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0008-2019-biopharma-alopecia-niche-rare-disease-landscape-forecast-us-eu5-2019\/","title":{"rendered":"Alopecia | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2019"},"content":{"rendered":"<p>Alopecia areata (<abbr title=\"alopecia areata\">AA<\/abbr>) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary treatment goal is to stimulate hair growth through the alleviation of inflammation at sites of hair loss. Topical corticosteroids and topical contact allergens are commonly prescribed for\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>; however, tolerability issues, side effects, and the modest efficacy of current treatment options underscore the substantial unmet clinical need in\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>. The\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0pipeline is active, consisting primarily of targeted immunomodulatory agents, and boasts several marketed and investigational\u00a0<abbr title=\"Janus kinase\">JAK<\/abbr>\u00a0inhibitors (e.g., Eli Lilly\u2019s Olumiant, Incyte\u2019s Jakafi, Concert\u2019s\u00a0CPT-543) and targeted biologics (e.g., Novartis\u2019s Cosentyx, LEO Pharma\u2019s tralokinumab). This report provides an analysis of\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0epidemiology, current disease management, unmet needs, and the clinical and commercial potential of emerging\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0therapies.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How large is the diagnosed\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0population, and how will its size change between 2018 and 2028? How large are the diagnosed alopecia totalis and universalis populations?<\/li>\n<li>What are the key unmet clinical needs in\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>, and to what degree will they be fulfilled by 2028?<\/li>\n<li>What is the current state of treatment in\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>, and how will it evolve over time?<\/li>\n<li>What emerging\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0therapies are viewed by treating dermatologists as most promising, and what sales\/uptake will they achieve in\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>? How will\u00a0<abbr title=\"Janus kinase\">JAK<\/abbr>\u00a0inhibitors fit into the\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0treatment algorithm?<\/li>\n<\/ul>\n<p>CONTENT HIGHLIGHTS<\/p>\n<ul>\n<li>Geographies: United States and\u00a0<abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>.<\/li>\n<li>Primary research: six country-specific interviews with thought-leading dermatologists supported by survey data collected for this study.<\/li>\n<li>Epidemiology: diagnosed and drug-treated prevalence of\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0by country.<\/li>\n<li>Forecast:\u00a0drug-level sales and patient share of key\u00a0<abbr title=\"alopecia areata\">AA<\/abbr>\u00a0therapies in 2028.<\/li>\n<li>Emerging therapies:\n<ul>\n<li>Phase II\/III: 4\u00a0drugs.<\/li>\n<li>Phase II: 11 drugs.<\/li>\n<li>Coverage of select preclinical and Phase I products.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<ul>\n<li><em>Niche &#038; Rare Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-409061","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409061\/revisions"}],"predecessor-version":[{"id":576614,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409061\/revisions\/576614"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=409061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}